Know Cancer

or
forgot password

Standardization of Breast Radiotherapy: Trial A - A Randomized Comparison of Fractionation Regimens After Local Excision or Mastectomy in Women With Early Stage Breast Cancer


Phase 3
18 Years
N/A
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

Standardization of Breast Radiotherapy: Trial A - A Randomized Comparison of Fractionation Regimens After Local Excision or Mastectomy in Women With Early Stage Breast Cancer


OBJECTIVES:

- Determine the benefits of radiotherapy schedules using fraction sizes larger than 2.0
Gy in terms of normal tissue responses, local-regional tumor control, quality of life,
and economic consequences in women prescribed postoperative radiotherapy for early
stage breast cancer.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
center, type of surgery (mastectomy vs local excision), and breast boost (yes vs no).
Patients are randomized to 1 of 3 treatment arms.

- Arm I: Patients receive radiotherapy 5 times a week for 5 weeks for a total dose of 50
Gy.

- Arm II: Patients receive radiotherapy 5 times a fortnight (i.e.,
Monday/Wednesday/Friday/Tuesday/Thursday/Monday, etc.) for 13 fractions over 5 weeks
for a total dose of 41.6 Gy.

- Arm III: Patients receive radiotherapy as in arm II for a total dose of 39 Gy. A breast
boost is recommended in all arms for patients with microscopic evidence of invasive or
in situ cancer at, or within 1 mm of, a resection margin. These patients receive
radiotherapy for 5 fractions in 1 week for a total boost dose of 10 Gy.

Quality of life is assessed at baseline and then at 6, 12, 24, and 60 months.

Patients are followed annually for up to 20 years.

PROJECTED ACCRUAL: A total of 2,010 patients (670 per arm) will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically confirmed invasive unilateral breast cancer that is considered
operable

- T1-3, N0-1, M0 at presentation

- Complete macroscopic excision of tumor by breast conserving surgery or mastectomy

- No immediate breast reconstruction

- No requirement for axillary radiotherapy after greater than a Level 1 axillary
dissection or after greater than 10 lymph nodes have been removed

- Not enrolled on SECRAB or OSCAR trials

- Hormone receptor status:

- Not specified

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Sex:

- Female

Menopausal status:

- Not specified

Performance status:

- Not specified

Life expectancy:

- Not specified

Hematopoietic:

- Not specified

Hepatic:

- Not specified

Renal:

- Not specified

PRIOR CONCURRENT THERAPY:

- Prior neoadjuvant, or primary medical, therapy allowed provided subsequent surgery
confirms complete macroscopic excision of residual primary tumor

Biologic therapy:

- Not specified

Chemotherapy:

- At least 2 weeks since prior cytotoxic agents

- No concurrent chemotherapy

Endocrine therapy:

- Not specified

Radiotherapy:

- See Disease Characteristics

Surgery:

- See Disease Characteristics

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Primary Purpose: Treatment

Principal Investigator

John R. Yarnold, MD, FRCR

Investigator Role:

Study Chair

Investigator Affiliation:

Royal Marsden NHS Foundation Trust

Authority:

United States: Federal Government

Study ID:

CDR0000067662

NCT ID:

NCT00005588

Start Date:

January 1999

Completion Date:

Related Keywords:

  • Breast Cancer
  • stage I breast cancer
  • stage II breast cancer
  • stage IIIA breast cancer
  • Breast Neoplasms

Name

Location